Financhill
Buy
54

CLPT Quote, Financials, Valuation and Earnings

Last price:
$14.90
Seasonality move :
20.69%
Day range:
$14.29 - $15.78
52-week range:
$5.11 - $17.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.43x
P/B ratio:
14.79x
Volume:
258.9K
Avg. volume:
258.3K
1-year change:
142.13%
Market cap:
$428.8M
Revenue:
$24M
EPS (TTM):
-$0.69

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CLPT
ClearPoint Neuro
$7.8M -$0.17 20.85% -14.04% --
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% --
INFU
InfuSystems Holdings
$34.5M $0.05 9.85% 1713.24% --
RVP
Retractable Technologies
-- -- -- -- --
VTAK
Catheter Precision
$290K -$2.60 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$29.3M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CLPT
ClearPoint Neuro
$15.55 -- $428.8M -- $0.00 0% 13.43x
CATX
Perspective Therapeutics
$2.85 -- $192.6M -- $0.00 0% 15.39x
INFU
InfuSystems Holdings
$8.31 -- $176.7M 131.26x $0.00 0% 1.35x
RVP
Retractable Technologies
$0.64 -- $19.2M -- $0.00 0% 0.50x
VTAK
Catheter Precision
$0.33 -- $2.6M 0.38x $0.00 0% 0.88x
XTNT
Xtant Medical Holdings
$0.36 -- $50M -- $0.00 0% 0.42x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CLPT
ClearPoint Neuro
-- 0.769 -- 3.37x
CATX
Perspective Therapeutics
-- -5.312 -- --
INFU
InfuSystems Holdings
33.51% 2.847 19.66% 1.37x
RVP
Retractable Technologies
1.55% 0.611 11.72% 5.80x
VTAK
Catheter Precision
12% -11.532 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 1.226 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CLPT
ClearPoint Neuro
$4.8M -$5.2M -50.18% -64.36% -63.68% -$1.2M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
INFU
InfuSystems Holdings
$19M $3.3M 1.77% 2.8% 9.23% $6.4M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

ClearPoint Neuro vs. Competitors

  • Which has Higher Returns CLPT or CATX?

    Perspective Therapeutics has a net margin of -61.24% compared to ClearPoint Neuro's net margin of --. ClearPoint Neuro's return on equity of -64.36% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLPT
    ClearPoint Neuro
    59.68% -$0.18 $29M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About CLPT or CATX?

    ClearPoint Neuro has a consensus price target of --, signalling upside risk potential of 9.36%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than ClearPoint Neuro, analysts believe Perspective Therapeutics is more attractive than ClearPoint Neuro.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLPT
    ClearPoint Neuro
    0 0 0
    CATX
    Perspective Therapeutics
    0 0 0
  • Is CLPT or CATX More Risky?

    ClearPoint Neuro has a beta of 1.084, which suggesting that the stock is 8.385% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock CLPT or CATX?

    ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLPT or CATX?

    ClearPoint Neuro quarterly revenues are $8.1M, which are larger than Perspective Therapeutics quarterly revenues of --. ClearPoint Neuro's net income of -$5M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 13.43x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLPT
    ClearPoint Neuro
    13.43x -- $8.1M -$5M
    CATX
    Perspective Therapeutics
    15.39x -- -- -$15.1M
  • Which has Higher Returns CLPT or INFU?

    InfuSystems Holdings has a net margin of -61.24% compared to ClearPoint Neuro's net margin of 5.12%. ClearPoint Neuro's return on equity of -64.36% beat InfuSystems Holdings's return on equity of 2.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLPT
    ClearPoint Neuro
    59.68% -$0.18 $29M
    INFU
    InfuSystems Holdings
    53.92% $0.08 $83.5M
  • What do Analysts Say About CLPT or INFU?

    ClearPoint Neuro has a consensus price target of --, signalling upside risk potential of 9.36%. On the other hand InfuSystems Holdings has an analysts' consensus of -- which suggests that it could grow by 69.98%. Given that InfuSystems Holdings has higher upside potential than ClearPoint Neuro, analysts believe InfuSystems Holdings is more attractive than ClearPoint Neuro.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLPT
    ClearPoint Neuro
    0 0 0
    INFU
    InfuSystems Holdings
    0 0 0
  • Is CLPT or INFU More Risky?

    ClearPoint Neuro has a beta of 1.084, which suggesting that the stock is 8.385% more volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.528, suggesting its more volatile than the S&P 500 by 52.819%.

  • Which is a Better Dividend Stock CLPT or INFU?

    ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLPT or INFU?

    ClearPoint Neuro quarterly revenues are $8.1M, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. ClearPoint Neuro's net income of -$5M is lower than InfuSystems Holdings's net income of $1.8M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 131.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 13.43x versus 1.35x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLPT
    ClearPoint Neuro
    13.43x -- $8.1M -$5M
    INFU
    InfuSystems Holdings
    1.35x 131.26x $35.3M $1.8M
  • Which has Higher Returns CLPT or RVP?

    Retractable Technologies has a net margin of -61.24% compared to ClearPoint Neuro's net margin of -18.58%. ClearPoint Neuro's return on equity of -64.36% beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLPT
    ClearPoint Neuro
    59.68% -$0.18 $29M
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About CLPT or RVP?

    ClearPoint Neuro has a consensus price target of --, signalling upside risk potential of 9.36%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that ClearPoint Neuro has higher upside potential than Retractable Technologies, analysts believe ClearPoint Neuro is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLPT
    ClearPoint Neuro
    0 0 0
    RVP
    Retractable Technologies
    0 0 0
  • Is CLPT or RVP More Risky?

    ClearPoint Neuro has a beta of 1.084, which suggesting that the stock is 8.385% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

  • Which is a Better Dividend Stock CLPT or RVP?

    ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios CLPT or RVP?

    ClearPoint Neuro quarterly revenues are $8.1M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. ClearPoint Neuro's net income of -$5M is lower than Retractable Technologies's net income of -$1.9M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 13.43x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLPT
    ClearPoint Neuro
    13.43x -- $8.1M -$5M
    RVP
    Retractable Technologies
    0.50x -- $10.3M -$1.9M
  • Which has Higher Returns CLPT or VTAK?

    Catheter Precision has a net margin of -61.24% compared to ClearPoint Neuro's net margin of -4291.67%. ClearPoint Neuro's return on equity of -64.36% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLPT
    ClearPoint Neuro
    59.68% -$0.18 $29M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About CLPT or VTAK?

    ClearPoint Neuro has a consensus price target of --, signalling upside risk potential of 9.36%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than ClearPoint Neuro, analysts believe Catheter Precision is more attractive than ClearPoint Neuro.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLPT
    ClearPoint Neuro
    0 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is CLPT or VTAK More Risky?

    ClearPoint Neuro has a beta of 1.084, which suggesting that the stock is 8.385% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

  • Which is a Better Dividend Stock CLPT or VTAK?

    ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLPT or VTAK?

    ClearPoint Neuro quarterly revenues are $8.1M, which are larger than Catheter Precision quarterly revenues of $96K. ClearPoint Neuro's net income of -$5M is lower than Catheter Precision's net income of -$4.1M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 13.43x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLPT
    ClearPoint Neuro
    13.43x -- $8.1M -$5M
    VTAK
    Catheter Precision
    0.88x 0.38x $96K -$4.1M
  • Which has Higher Returns CLPT or XTNT?

    Xtant Medical Holdings has a net margin of -61.24% compared to ClearPoint Neuro's net margin of -17.98%. ClearPoint Neuro's return on equity of -64.36% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLPT
    ClearPoint Neuro
    59.68% -$0.18 $29M
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About CLPT or XTNT?

    ClearPoint Neuro has a consensus price target of --, signalling upside risk potential of 9.36%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than ClearPoint Neuro, analysts believe Xtant Medical Holdings is more attractive than ClearPoint Neuro.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLPT
    ClearPoint Neuro
    0 0 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is CLPT or XTNT More Risky?

    ClearPoint Neuro has a beta of 1.084, which suggesting that the stock is 8.385% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

  • Which is a Better Dividend Stock CLPT or XTNT?

    ClearPoint Neuro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ClearPoint Neuro pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLPT or XTNT?

    ClearPoint Neuro quarterly revenues are $8.1M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. ClearPoint Neuro's net income of -$5M is higher than Xtant Medical Holdings's net income of -$5M. Notably, ClearPoint Neuro's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ClearPoint Neuro is 13.43x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLPT
    ClearPoint Neuro
    13.43x -- $8.1M -$5M
    XTNT
    Xtant Medical Holdings
    0.42x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is down 2.13% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 2.88% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 6.16% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock